文献速递乳腺癌

德曲妥珠单抗用于HR阳性HER2低表达/超低表达转移性乳腺癌:DESTINY-Breast06按一线内分泌联合CDK4/6抑制剂进展时间及基线肿瘤负荷分层结局分析

Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease.
PubMed 文献 · Ann Oncol · 2026-03-02

DESTINY-Breast06研究事后分析纳入866例HR阳性HER2低表达/超低表达转移性乳腺癌患者,按一线内分泌治疗联合CDK4/6抑制剂后进展时间及基线疾病负荷分层。结果显示,无论进展时间短于6个月、6至12个月或超过12个月,德曲妥珠单抗组中位无进展生存期均优于医生选择化疗组;在原发性或继发性内分泌抵抗及高或低疾病负荷各亚组中,德曲妥珠单抗均一致获益,安全性特征与总体人群一致。

要点

  • 一线内分泌联合CDK4/6抑制剂后进展时间不足6个月者,德曲妥珠单抗中位PFS 14.0个月,化疗6.5个月。
  • 进展时间6至12个月者中位PFS为13.2个月对6.9个月,超过12个月者为12.9个月对8.2个月。
  • 各亚组客观缓解率和缓解持续时间均倾向德曲妥珠单抗,且PFS2亦延长。

核心结论

  • 德曲妥珠单抗对HR阳性HER2低表达/超低表达转移性乳腺癌经一种或以上内分泌治疗后广泛有效,不受一线内分泌联合CDK4/6抑制剂进展时间、内分泌抵抗类型或疾病负荷影响。

研究设计与样本

  • DESTINY-Breast06研究的事后亚组分析,纳入意向治疗人群866例,按1:1随机分配接受德曲妥珠单抗5.4 mg/kg每3周一次或医生选择化疗。

主要发现

  • 一线内分泌联合CDK4/6抑制剂后进展时间不足6个月者,德曲妥珠单抗组中位PFS为14.0个月(95%CI 11.2-15.9),化疗组为6.5个月(95%CI 4.2-8.4)。
  • 进展时间6至12个月者,德曲妥珠单抗组中位PFS为13.2个月(95%CI 8.6-16.4),化疗组为6.9个月(95%CI 4.3-10.4)。
  • 进展时间超过12个月者,德曲妥珠单抗组中位PFS为12.9个月(95%CI 9.8-17.1),化疗组为8.2个月(95%CI 6.9-10.9)。
  • 所有亚组中,德曲妥珠单抗组确认客观缓解率为36.7%至67.7%,化疗组为16.7%至37.5%,且德曲妥珠单抗组中位缓解持续时间更长。
  • 德曲妥珠单抗在各亚组中均较化疗延长PFS2,安全性特征与总体安全性人群一致。

关键数值与推荐

  • 亚组依据一线内分泌治疗联合CDK4/6抑制剂后进展时间划分:不足6个月、6至12个月、超过12个月。
  • 疾病负荷指标包括内脏/非内脏疾病、肝转移有/无、疾病部位三个及以上/不足三个、基线肿瘤大小大于/小于等于中位数。
  • 内分泌抵抗分为原发性或继发性。

临床怎么用

  • 对于HR阳性HER2低表达/超低表达转移性乳腺癌经内分泌治疗进展后,德曲妥珠单抗可作为不受进展时间、内分泌抵抗类型或疾病负荷限制的治疗选择。

局限性

  • 亚组分析为事后设定,来自意向治疗人群,需谨慎解读亚组结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In DESTINY-Breast06, trastuzumab deruxtecan (T-DXd) improved progression-free survival (PFS) versus physician's choice of chemotherapy (TPC) for patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-low/-ultralow metastatic breast cancer (mBC), without new safety signals. We report additional analyses exploring outcomes for patients with characteristics that affect prognosis. PATIENTS AND METHODS: Patients were randomly assigned 1 : 1 to receive T-DXd (5.4 mg/kg) once every 3 weeks or TPC. Subgroups were specified post hoc from the intent-to-treat population (N = 866). Outcomes were PFS, objective response rate (ORR), and duration of response (DOR) by blinded independent central review via RECIST 1.1. Time from randomization until second progression or death (PFS2) by investigator and safety were also assessed. RESULTS: Within subgroups, baseline disease characteristics and prior therapies were balanced across treatments. Median PFS (95% confidence interval) favored T-DXd versus TPC regardless of time to progression (TTP) on prior first-line endocrine therapy (ET) + cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i): <6 months: 14.0 (11.2-15.9) versus 6.5 (4.2-8.4) months for T-DXd versus TPC; 6-12 months: 13.2 (8.6-16.4) versus 6.9 (4.3-10.4) months; >12 months: 12.9 (9.8-17.1) versus 8.2 (6.9-10.9) months. A consistent PFS benefit with T-DXd over TPC was observed for patients with primary or secondary endocrine resistance, and across indicators of high or low disease burden (defined as visceral/non-visceral disease, presence/absence of liver metastases, three or more/less than three disease sites, and >median/≤median baseline tumor size). In all subgroups, confirmed ORR favored T-DXd (36.7% to 67.7%) versus TPC (16.7% to 37.5%), and median DOR (confirmed response) was longer with T-DXd. T-DXd also prolonged PFS2 versus TPC across subgroups. Safety profiles of T-DXd and TPC in subgroups were consistent with the overall safety population. CONCLUSIONS: These data support T-DXd as a broadly efficacious treatment for patients with HR-positive, HER2-low/-ultralow mBC after one or more ETs, regardless of TTP on prior first-line ET + CDK4/6i, endocrine resistance, or disease burden.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Curigliano G, Hu X, Dent R, et al. Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease. Ann Oncol. 2026. PMID: 41780642. doi:10.1016/j.annonc.2026.02.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。